Form 4: Century Therapeutics Executive Sells Shares to Cover Tax Obligations, Receives Stock Options and Restricted Stock Units

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units and received new stock options and restricted stock units.

Summary

• Gregory Russotti, the Chief Technology and Manufacturing Officer of Century Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On March 10, 2025, Russotti sold 2,360 shares of common stock at $0.615 per share to cover tax withholding obligations related to vesting restricted stock units (RSUs).
• On March 11, 2025, Russotti was granted 120,000 restricted stock units (RSUs) and a stock option to purchase 120,000 shares at an exercise price of $0.601.
• The RSUs vest 25% on March 11, 2026, and the remaining 75% vest quarterly over the following three years, contingent upon continued service.
• The stock option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, also contingent upon continued service.
• Following these transactions, Russotti directly owns 392,573 shares of Century Therapeutics common stock and indirectly owns 92,773 shares through the Gregory Russotti 2021 Family Trust.

Sentiment

Score: 6

Explanation: The document primarily reflects routine transactions related to executive compensation. The sale of shares for tax purposes is neutral, and the grant of RSUs and stock options is generally positive as it incentivizes the executive. Overall, the sentiment is slightly positive.

Positives

• The grant of RSUs and stock options to a key executive like the Chief Technology and Manufacturing Officer can be seen as an incentive to remain with the company and drive future growth.
• The vesting schedules for the RSUs and stock options encourage long-term commitment from the executive.

Negatives

• The sale of shares, even for tax obligations, could be perceived negatively by some investors, although it is a common practice.

Risks

• The vesting of RSUs and stock options is contingent upon the Reporting Person's continued service, so there is a risk that the executive may leave the company before the awards fully vest.
• The value of the shares sold to cover tax obligations is subject to market fluctuations, which could impact the executive's overall compensation.

Future Outlook

The document outlines the vesting schedule for the granted RSUs and stock options, indicating the future potential for the executive to acquire additional shares of Century Therapeutics stock, contingent on continued service.

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ('RSUs').
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

In the biotechnology industry, it is common for companies to grant stock options and restricted stock units to executives as part of their compensation packages to align their interests with those of shareholders and incentivize long-term performance. This filing reflects a typical compensation practice within the sector.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice in the biotech industry, used by companies like Amgen, Gilead Sciences, and Biogen to incentivize executives.
• Vesting schedules, such as the one described (25% after one year, then quarterly or monthly), are common to ensure continued service and alignment with long-term company goals.
• The exercise price of $0.601 for the stock options is typical, often set at or near the market price at the time of the grant.

Stakeholder Impact

• Shareholders may view the grant of RSUs and stock options positively as it aligns executive interests with long-term company performance.
• Employees may see the executive compensation package as a sign of the company's commitment to its leadership.

Key Dates